Accueil   Diary - News   All news Adocia initiates a clinical study on the post-meal effect of ultrarapid BioChaperone Lispro insulin formulation

Adocia initiates a clinical study on the post-meal effect of ultrarapid BioChaperone Lispro insulin formulation

Adocia announces the initiation of a Phase Ib clinical trial evaluation for BioChaperone Lispro, an ultra-rapid formulation of insulin lispro licensed to Eli Lilly and Company. This formulation uses Adocia’s proprietary technology BioChaperone, which is believed to enable the acceleration of insulin absorption.

This is the first study to be initiated as part of the Adocia-Lilly partnership. The study aims to measure the effect of BioChaperone Lispro, injected at the time of a standardized meal, on post-meal glycemic control in type 1 diabetes patients and compare this effect to that of Humalog®(insulin lispro rDNA origin). Commercialized fast-acting insulin analogs are usually injected before the meal. An ultra-rapid insulin, meanwhile, aims to allow injection at the time of the meal, or even after the start of a meal, with the goal of reducing the magnitude of glycemic excursions. This study will be sponsored by Adocia, and performed by Profil in Germany.


Read the press release

 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree